The POLO (Pancreas Cancer Olaparib Ongoing) trial demonstrated improvement in progression-free survival (PFS) with olaparib maintenance in advanced pancreatic cancer (APC) patients with germline BRCA1/2 mutations who had disease control after 16 weeks of platinum-based first-line therapy. However, in the real-world, the first assessment is usually performed at 12 weeks. Therefore, this study aimed to identify the proportion of real-world patients with APC that have disease control at 12 weeks (DC12) after FOLFIRINOX, assess any associations of baseline variables with DC12, and to determine the effect of DC12 on PFS and overall survival (OS).

中文翻译：

---

接受 FOLFIRINOX 作为一线化疗的晚期胰腺癌患者 12 周时疾病控制的预后意义。

POLO（胰腺癌奥拉帕尼正在进行）试验表明，携带种系 BRCA1/2 突变的晚期胰腺癌 (APC) 患者接受奥拉帕尼维持治疗后，无进展生存期 (PFS) 有所改善，且在接受 16 周铂类一线治疗后疾病得到控制。治疗。然而，在现实世界中，第一次评估通常在 12 周时进行。因此，本研究旨在确定 FOLFIRINOX 治疗后 12 周 (DC12) 时疾病控制的现实世界 APC 患者的比例，评估基线变量与 DC12 的任何关联，并确定 DC12 对 PFS 和总生存期的影响（操作系统）。